-
RBC Sees Big Upside in Aerie Pharma (AERI) Ahead of Roclatan Phase 3 Data in September
-
RBC Capital Comments Following Weakness in Shares of Aerie Pharma (AERI)
-
Aerie Pharmaceuticals to Present at the RBC Capital Markets 2016 Healthcare Conference
-
RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
-
Aerie Pharma (AERI) Price Target Raised to $31 at RBC Capital
-
Aerie Pharma (AERI) Price Target Lowered to $27 at RBC
-
Aerie Pharma (AERI) Weakness Seen as Buying Opportunity at RBC
-
Notable Analyst Rating Changes 07/03: (CREE) (ATHL) (TS) Upgraded; (RMD) (RGDO) ((NFX) Downgraded
-
RBC Capital Starts Aerie Pharma (AERI) at Outperform
-
Aerie Pharmaceuticals (AERI) IPO Opens Modestly Higher
-
aerie pharmaceuticals (AERI) Sees IPO Price of $12 - $14/Share
-
aerie pharmaceuticals (AERI) Files $57.5M IPO